logo-loader
viewNetscientific PLC

Majority of NetScientific portfolio now at early commercial stage

Francois Martelet, chief executive of NetScientific PLC (LON:NSCI), tells Proactive's Andrew Scott they're starting 2018 in a very strong position.

''Out of our five companies, three of them are at an early commercial stage''.

As far the broader strategic plan for 2018, he says the main focus is to continue helping the current portfolio to mature

'We're also looking at having new investors and the sector is also looking for consolidation .. so M&A is also part of our plans ''.

Quick facts: Netscientific PLC

Price: 6 GBX

AIM:NSCI
Market: AIM
Market Cap: £4.71 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19

2 min read